Cantor Fitzgerald analyst Eliana Merle raised her price target for uniQure to $96 from $94 and reiterates an Overweight rating on the shares. uniQure has a "robust and differentiated gene therapy platform that remains underappreciated," Merle tells investors in a research note. The analyst sees further shares upside and views the company as a "highly attractive" takeover candidate, with an estimate a fair value based on the current pipeline of at least $110 to $140 per share on a buyout. And on fundamental basis alone, Merle sees upside as the company enters the next chapter both for hemophilia B and for Huntington's.